LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Lipocine Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$1.53−0.03 (-1.92%)

Close on Oct 19, 2026

Market cap: $12.57M
P/E (TTM): –
Dividend yield: –

SEC filings

40 of Lipocine's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Oct 20, 2026	Oct 20, 2026	SEC EDGAR
Current report	8-K	Oct 7, 2026	Oct 7, 2026	SEC EDGAR
Current report	8-K	Sep 16, 2026	Sep 16, 2026	SEC EDGAR
Current report	8-K	Sep 14, 2026	Sep 14, 2026	SEC EDGAR
Current report	8-K	Sep 8, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	8-K	Aug 4, 2026	Aug 4, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 4, 2026	SEC EDGAR
Current report	8-K	Aug 3, 2026	Aug 3, 2026	SEC EDGAR
Current report	8-K	Jun 12, 2026	Jun 12, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	Jun 4, 2026	Jun 4, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	May 26, 2026	SEC EDGAR
Current report	8-K	May 19, 2026	May 19, 2026	SEC EDGAR
Current report	8-K	May 18, 2026	May 18, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 21, 2026	Apr 21, 2026	SEC EDGAR
Current report	8-K	Apr 16, 2026	Apr 21, 2026	SEC EDGAR
Current report	8-K	Apr 2, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Apr 2, 2026	Apr 2, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 10, 2026	SEC EDGAR
Current report	8-K	Feb 26, 2026	Mar 4, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 18, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 18, 2026	SEC EDGAR
Current report	8-K	Jan 20, 2026	Jan 20, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Dec 15, 2025	Dec 16, 2025	SEC EDGAR
Current report	8-K	Dec 12, 2025	Dec 15, 2025	SEC EDGAR
Current report	8-K	Dec 8, 2025	Dec 11, 2025	SEC EDGAR
Current report	8-K	Nov 18, 2025	Nov 18, 2025	SEC EDGAR
Current report	8-K	Nov 18, 2025	Nov 18, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 4, 2025	Nov 4, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Sep 30, 2025	SEC EDGAR
Current report	8-K	Sep 26, 2025	Sep 26, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Lipocine's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-17 reverse split on Aug 10, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LPCN.

Operating margin-800.8% · median -3235.5%

Net margin-755.1% · median -2440.8%

Company	Revenue	Growth
VTGN	$2.50M	–
OVID	$1.58M	-76.2%
LPCN	$1.57M	-62.7%
SPRB	–	–
ATXI	–	–
ORMP	–	–

Company

Next earnings (est.): Nov 5, 2026, during market hours
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 14
Held by institutions: 36.2%
Auditor: Tanner LLP
SEC CIK: 1535955

Advertisement
300 × 250